Driehaus Capital NPCE Position
Active3-Fund ConvergenceDriehaus Capital increased their position in NeuroPace Inc (NPCE) in Q4 2025, holding $23.3M worth of shares across 1,511,289 shares.
The position was first reported in Q1 2025 and has been tracked across 4 quarterly 13F filings.
NPCE is a convergence signal: 3 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout in 41 days (May 31, 2026), making the timing of Driehaus's position particularly relevant.
About NeuroPace Inc
NeuroPace, Inc. operates as a medical device company in the United States. It develops and sells RNS system, a brain-responsive neuromodulation system for treating medically refractory focal epilepsy by delivering personalized real-time treatment at the seizure source. The company's RNS system also records continuous brain activity data; and enables clinicians to monitor patients in person and remotely. It sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. The company was incorporated in 1997 and is headquartered in Mountain View, California.
Full company profile →Short Interest
4.7%
3.6 days to cover
Driehaus Capital NPCE Position History
Frequently Asked Questions
Does Driehaus Capital own NPCE?
Yes. As of Q4 2025, Driehaus Capital holds 1,511,289 shares of NeuroPace Inc (NPCE) valued at $23.3M. This data comes from their SEC 13F filing.
How many hedge funds own NPCE?
3 specialist biotech hedge funds currently hold NPCE, including OrbiMed Advisors, Deerfield Management. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Driehaus Capital first buy NPCE?
Driehaus Capital's position in NPCE was first reported in Q1 2025. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Driehaus Capital's NPCE position increasing or decreasing?
Driehaus Capital increased their NPCE position in the most recent quarter, adding 571,770 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
NPCECompany Page →
All fund holders, insider trades, catalysts, and cash runway
Driehaus CapitalPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →